logo
#

Latest news with #ShaneStorey

Wilsons Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)
Wilsons Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)

Business Insider

time17-06-2025

  • Business
  • Business Insider

Wilsons Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)

Wilsons analyst Shane Storey maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) on June 15 and set a price target of A$8.25. The company's shares opened today at A$2.30. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Storey is a 4-star analyst with an average return of 7.3% and a 48.19% success rate. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. Currently, the analyst consensus on Clarity Pharmaceuticals Ltd. is a Strong Buy with an average price target of A$6.15, representing a 167.39% upside. In a report released on June 10, Bell Potter also maintained a Buy rating on the stock with a A$4.90 price target. The company has a one-year high of A$8.98 and a one-year low of A$1.43. Currently, Clarity Pharmaceuticals Ltd. has an average volume of 2.95M.

Monash IVF Group Ltd (MVF) Gets a Buy from Wilsons
Monash IVF Group Ltd (MVF) Gets a Buy from Wilsons

Business Insider

time12-06-2025

  • Business
  • Business Insider

Monash IVF Group Ltd (MVF) Gets a Buy from Wilsons

In a report released today, Shane Storey from Wilsons maintained a Buy rating on Monash IVF Group Ltd (MVF – Research Report), with a price target of A$1.25. The company's shares opened today at A$0.64. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Storey is a 4-star analyst with an average return of 7.8% and a 50.91% success rate. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. Monash IVF Group Ltd has an analyst consensus of Strong Buy, with a price target consensus of A$1.11, implying a 73.44% upside from current levels. In a report released yesterday, Macquarie also maintained a Buy rating on the stock with a A$1.30 price target.

Wilsons Sticks to Their Buy Rating for EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)
Wilsons Sticks to Their Buy Rating for EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)

Business Insider

time30-05-2025

  • Business
  • Business Insider

Wilsons Sticks to Their Buy Rating for EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR)

Wilsons analyst Shane Storey maintained a Buy rating on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR – Research Report) yesterday and set a price target of A$3.00. The company's shares opened today at A$1.09. Confident Investing Starts Here: Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Monash IVF Group Ltd, and EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh. According to TipRanks, Storey has an average return of 7.5% and a 50.62% success rate on recommended stocks. EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an analyst consensus of Strong Buy, with a price target consensus of A$2.80, implying a 156.88% upside from current levels. In a report released on May 25, Bell Potter also maintained a Buy rating on the stock with a A$2.25 price target. The company has a one-year high of A$2.08 and a one-year low of A$0.82. Currently, EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh has an average volume of 1.08M.

Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)
Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Business Insider

time12-05-2025

  • Business
  • Business Insider

Wilsons Reaffirms Their Buy Rating on Telix Pharmaceuticals (TLPPF)

Wilsons analyst Shane Storey maintained a Buy rating on Telix Pharmaceuticals (TLPPF – Research Report) on May 8 and set a price target of A$35.00. The company's shares closed last Friday at $17.88. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. Storey covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, Nanosonics Limited, and Opthea . According to TipRanks, Storey has an average return of 9.9% and a 53.46% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Telix Pharmaceuticals with a $21.77 average price target, representing a 21.79% upside. In a report released on April 29, Bell Potter also maintained a Buy rating on the stock with a A$34.00 price target. The company has a one-year high of $24.85 and a one-year low of $9.60. Currently, Telix Pharmaceuticals has an average volume of 7,300.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store